The caliber of the advisers is remarkable. Those susceptible to short BS will not appreciate the significance of these experts joining the Cytodyn team.

This is, IMO, a generational discovery and opportunity. A PR on advisers will not help those who do not already appreciate the transformation leronlimab will shortly unleash.

I do hate the shorts, but something I am resigned to.